Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. develops allosteric small molecule therapies for neurodegenerative and other difficult-to-treat diseases. The company’s lead candidate, GT-02287, is being developed for Parkinson’s disease with or without a GBA1 mutation and is designed as a brain-penetrant allosteric enzyme modulator of glucocerebrosidase, or GCase.
Recurring news for GANX includes financial results, corporate updates, clinical and biomarker data for GT-02287, FDA and IND-related communications, and scientific presentations at Parkinson’s and neurodegeneration conferences. Company updates also cover the Magellan™ drug discovery platform, preclinical GCase modulator programs such as GT-04686, and pipeline areas including lysosomal storage disorders, metabolic diseases and solid tumors.
Gain Therapeutics, Inc. (NASDAQ: GANX) announced its STAR candidate for Parkinson's disease has been selected among the 10 Best Abstracts at the IAPRD 2021 World Congress. The poster presentation, led by Roberto Maj, Pharm.D., showcases the potential of the company's structurally targeted allosteric regulators (STARs) to improve motor deficits in an in vivo model of Parkinson's disease. The conference will be held virtually from May 1-4, 2021, and the presentation will remain accessible throughout the event.
Gain Therapeutics, Inc. (NASDAQ: GANX) announced a multi-target collaboration with Zentalis Pharmaceuticals (NASDAQ: ZNTL) to identify new oncology drug targets using its proprietary SEE-Tx computational platform. This technology employs supercomputers to analyze protein structures for novel binding sites, enhancing drug discovery. Gain's CEO highlighted Zentalis' expertise in cancer treatments as a key asset for validating the SEE-Tx platform. This partnership aims to address challenges in cancer treatment through innovative target identification.
Gain Therapeutics, Inc. has successfully closed its initial public offering (IPO) of 3,636,364 shares of common stock, including the full exercise of the underwriters’ overallotment option for an additional 545,454 shares at a public offering price of $11.00 each. The gross proceeds from this offering amount to approximately $46 million, prior to deductions for underwriting discounts and expenses. Gain's shares are traded on the Nasdaq Global Market under the symbol GANX. The registration statement for this offering was made effective by the SEC on March 17, 2021.
Gain Therapeutics, Inc. has priced its initial public offering (IPO) at $11.00 per share, offering 3,636,364 shares under the symbol 'GANX'. Trading is set to commence on March 18, 2021, with the offering expected to close on March 22, 2021, subject to customary conditions. Underwriters hold a 30-day option to purchase an additional 545,454 shares. The SEC declared the registration statement effective on March 17, 2021. Gain Therapeutics aims to transform drug discovery with its See-Tx™ platform, targeting challenging disorders linked to protein misfolding.